Cardioprotective effect of renalase in 5/6 nephrectomized rats

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 17, Issue 4, 2012, Pages 412-416

  Baraka, A ^a   El Ghotny, S ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

cardiovascular disease; hypertrophy; left ventricular hypertrophy; renal

Indexed keywords

CREATININE; HYDROXYPROLINE; NITROGEN; NORADRENALIN; PHOSPHATE BUFFERED SALINE; RECOMBINANT ENZYME; RECOMBINANT RENALASE; UNCLASSIFIED DRUG; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; HEART LEFT VENTRICLE; HEART PAPILLARY MUSCLE; HEART PROTECTION; MALE; MEAN ARTERIAL PRESSURE; MORTALITY; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; UREA NITROGEN BLOOD LEVEL;

ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; ENZYME REPLACEMENT THERAPY; HEART VENTRICLES; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INJECTIONS, SUBCUTANEOUS; MALE; MONOAMINE OXIDASE; NEPHRECTOMY; PAPILLARY MUSCLES; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX; SUS SCROFA;

EID: 84868572007     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248412446977     Document Type: Article

References (30)

1. Mailloux LU, Haley WE. Hypertension in the ESRD patient: pathophysiology, therapy, outcomes, and future directions. Am J Kidney Dis. 1998 ; 32 (5). 705-719
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004 ; 351 (13). 1296-1305
3. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimbürger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?. Clin J Am Soc Nephrol. 2008 ; 3 (2). 505-521
4. Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med. 1999 ; 340 (17). 1321-1328
5. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002 ; 105 (11). 1354-1359
6. Xu J, Li G, Wang P. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest. 2005 ; 115 (5). 1275 1280
7. Eikelis N, Hennebry SC, Lambert GW, Schlaich MP. Does renalase degrade catecholamines?. Kidney Int. 2011 ; 79 (12). 1380-1381
8. Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol. 2001 ; 12 (5). 1079-1084
9. Desir GV. Role of renalase in the regulation of blood pressure and the renal dopamine system. Curr Opin Nephrol Hypertens. 2011 ; 20 (1). 31-36
10. Ghosh SS, Krieg RJ, Sica DA, Wang R, Fakhry I, Gehr T. Cardiac hypertrophy in neonatal nephrectomized rats: the role of the sympathetic nervous system. Pediatr Nephrol. 2009 ; 24 (2). 367-377
11. Westermann J, Hubl W, Kaiser N, Salewski L. Simple, rapid and sensitive determination of epinephrine and norepinephrine in urine and plasma by non-competitive enzyme immunoassay, compared with HPLC method. Clin Lab. 2002 ; 48 (1-2). 61-71
12. Zilva JF, Pannal PR, Mayne PD Clinical Chemistry in Diagnosis and Treatment. 5 th ed. London, Melbourne, Auckland: Edward Arnold; 1987. Chapter 1:1-24. London, Melbourne, Auckland: Edward Arnold ; 1987:
13. Richards JF, Smith RV, Wilcox RE. Comparison of two spectrophotometric assays for blood urea nitrogen: influence of apomorphine. Microchem J. 1984 ; 29 (1). 49-55
14. Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension. 2003 ; 42 (1). 49-55
15. Bing OH, Wiegner AW, Brooks WW, Fishbein MC, Pfeffer JM. Papillary muscles structure function relations in the aging spontaneously hypertensive rat. Clin Exp Hypertens. 1988 ; 10 (1). 37-58
16. Woessner JF. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys. 1961 ; 93: 440-447
17. Winer BJ Statistical Principles in Experimental Design. 2 nd ed. New York, NY: McGraw-Hill; 1971. New York, NY: McGraw-Hill ; 1971:
18. Przybylowski P, Malyszko J, Kozlowska S, Malyszko J, Koc-Zorawska E, Mysliwiec M. Serum renalase depends on kidney function but not on blood pressure in heart transplant recipients. Transplant Proc. 2011 ; 43 (10). 3888-3891
19. Li G, Xu J, Wang P, et al. Catecholamines regulate the activity, secretion, and synthesis of renalase. Circulation. 2008 ; 117 (10). 1277-1282
20. Ghosh SS, Gehr TWB, Sica DA, et al. Effect of renalase inhibition on blood pressure. J Am Soc Nephrol. 2006 ; 17: 208A
21. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension. 2004 ; 43 (4). 699-706
22. Gu R, Lu W, Xie J, Bai J, Xu B. Renalase deficiency in heart failure model of rats-a potential mechanism underlying circulating norepinephrine accumulation. PLoS One. 2011 ; 6 (1). e14633
23. Zoccali C, Mallamaci F, Tripepi G, et al. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension. 2002 ; 40 (1). 41-46
24. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the ß adrenergic pathway. Circulation. 1998 ; 98 (13). 1329-1334
25. Mann DL, Kent RL, Parsons B, Cooper G. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992 ; 85 (2). 790-804
26. Meredith IT, Broughton A, Jennings GL, Esler MD. Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med. 1991 ; 325 (9). 618-624
27. Farzaneh-Far R, Desir GV, Na B, Schiller NB, Whooley MA. A functional polymorphism in renalase (Glu37Asp) is associated with cardiac hypertrophy, dysfunction, and ischemia: data from the heart and soul study. PLoS One. 2010 ; 5 (10). e13496
28. Simpson P. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an ±1 adrenergic response. J Clin Invest. 1983 ; 72 (2). 732-738
29. Strauer Be, Bayer F, Brecht HM, Motz W. The influence of sympathetic nervous activity on regression of cardiac hypertrophy. J Hypertens. 1985 ; 3 (suppl 4). 39
30. Guérin AP, Pannier B, Marchais SJ, London GM. Arterial structure and function in end-stage renal disease. Curr Hypertens Rep. 2008 ; 10 (2). 107-111